Century Therapeutics GAAP EPS of -$0.14, revenue of $109.2M
Source: SeekingAlpha
2026-03-12 15:14:47 ET
More on Century Therapeutics
- Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race
- Century Therapeutics gains on $135M private placement
- Seeking Alpha’s Quant Rating on Century Therapeutics
- Historical earnings data for Century Therapeutics
- Financial information for Century Therapeutics
Read the full article on Seeking Alpha
For further details see:
Century Therapeutics GAAP EPS of -$0.14, revenue of $109.2M
Century Therapeutics Inc.
NASDAQ: IPSC
IPSC Trading
-2.67% G/L:
$2.37 Last:
521,736 Volume:
$2.44 Open:
IPSC Latest News
March 12, 2026 08:00:00 am
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates
February 25, 2026 08:00:00 am
Century Therapeutics to Participate in Upcoming Investor Conferences in March
IPSC Stock Data
$358,397,419
106,369,480
5.86%
10
N/A
Biotechnology & Life Sciences
Healthcare
US
Philadelphia
